TRPV2 and central nervous system cancer: TRPV2 expression decreases during glioma progression to higher clinical stages; TRPV2 negatively controls glioma cell survival and proliferation and protects cells from Fas-induced apoptosis in an ERK-dependent manner (Nabissi et al., 2010).